Pharmacological effects of lysozyme on COPD and bronchial asthma with sputum: A randomized, placebo-controlled, small cohort, cross-over study

Pulmonary Pharmacology and Therapeutics

Volumn 37, Issue , 2016, Pages 73-80

  Ohbayashi, Hiroyuki ^a   Setoguchi, Yasuhiro ^b   Fukuchi, Yoshinosuke ^c   Shibata, Kai ^d   Sakata, Yukinori ^d   Arai, Toshihisa ^d  

^a Tohno Chuo Clinic   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d EISAI CO LTD   (Japan)

Author keywords

Bronchial asthma (BA); Chronic obstructive pulmonary disease (COPD) management; Impulse oscillometry system (IOS); Lysozyme; Mucolytic agent; Spirometry

Indexed keywords

LYSOZYME CHLORIDE; PLACEBO; EXPECTORANT AGENT; LYSOZYME; NITRIC OXIDE;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMPULSE OSCILLOMETRY SYSTEM; MALE; OSCILLOMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; RESPIRATORY SYSTEM; SPIROMETRY; SPUTUM; UNSPECIFIED SIDE EFFECT; DYSPNEA; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASTHMA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSPNEA; EXPECTORANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MURAMIDASE; NITRIC OXIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SPIROMETRY; SPUTUM; TREATMENT OUTCOME;

EID: 84960407166     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2016.03.001     Document Type: Article

References (36)

1. 1 decline and chronic obstructive pulmonary disease morbidity. Cph. City Heart Study Grp. Am. J. Respir. Crit. Care Med. 1996, 153:1530-1535.
2. Fukuchi Y., Aizawa H., Ichinose M., Mishima M., Kubo K., Nagai A., et al. Clinical effects of carbocisteine on exacerbation in patients with COPD (PEACE study). KoKyu 2007, 26(10):955-963.
3. Zheng J.P., Kang J., Huang S.G., Chen P., Yao W.Z., Yang L., et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet 2008, 371:2013-2018.
4. Decramer M., Rutten-van Mölken M., Dekhuijzen P.N., Troosters T., van Herwaarden C., Pellegrino R., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on NAC cost-utility study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005, 365:1552-1560.
5. Malerba M., Ponticiello A., Radaeli A., Bensi G., Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST trail). Pulm. Pharmacol. Ther. 2004, 17:27-34.
6. Japanese Society of Allergology Asthma Prevention and Management Guideline 2012, Japan 2012, Kyowa Kikaku Press.
7. Dajani R., Zhang Y., Taft P.J., Travis S.M., Starner T.D., Olsen A., et al. Lysozyme secretion by submucosal glands protects the airway from bacterial infection. Am. J. Respir. Cell Mol. Biol. 2005, 32(6):548-552.
8. Ellison R.T., Giehl T.J. Killing of gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 1991, 88(4):1080-1091.
9. Thompson A.B., Bohling T., Payvandi F., Rennard S.I. Lower respiratory tract lactoferrin and lysozyme arise primarily in the airways and are elevated in association with chronic bronchitis. J. Lab. Clin. Med. 1990, 115(2):148-158.
10. Gordon L.I., Douglas S.D., Kay N.E., Yamada O., Osserman E.F., Jacob H.S. Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation. J. Clin. Invest. 1979, 64:226-232.
11. ®) on foreign materials excretion by tracheal mucociliary transport. Jpn. Pharmacol. Ther. 1997, 25(9):2347-2358.
12. Kayama S., Fukuchi Y., Harasawa M. An experimental study in the influence of age various drugs on ciliary beat frequency. Jpn. Pharmacol. Ther. 1985, 13:701-705.
13. Ishibashi Y., Takayama G., Inouye Y., Taniguchi A. Carbocisteine normalizes the viscous property of mucus through regulation of fucosylated and sialylated sugar chain on airway mucins. Eur. J. Pharmacol. 2010, 641:226-228.
14. Nagaoka S., Yamanaka E., Haga T., Matsuda M., Asakura H., Matsuda Y., et al. Objective appraisal of the efficacy of lysozyme hydrochloride (neuzym tablet) as an expectorant. Clin. Rep. 1981, 15:5879-5888.
15. Nagaoka S., Nakamura S., Yamanaka E., Katano F. The effect of the preparation of lysozyme hydrochloride on sputum. Ther. Res. 1986, 15(2):371-377.
16. Tanaka K., Mikami M., Ishikawa T., Shuto H., Kaneshige H., Kihara N., et al. The study of lysozyme chloride on the relationship between the chances of symptoms and physiochemical properties of sputum in chronic pulmonary disease. Jpn. J. Med. Pharm. Sci. 2005, 53(5):581-600.
17. Mitsui S., Hosokawa H., Komatsu M., Akasaka K., Ono Y., Kawakami Y., et al. Therapeutic efficacy of lysozyme on the difficulty of expectoration. Jpn. J. Chest Dis. 1975, 34(9):708-716.
18. Sato K. Clinical studies on chronic pulmonary disease - combination therapy with lysozyme chloride and ambroxol hydrochrolide. Jpn. J. Med. Pharm. Sci. 1991, 26(4):827-838.
19. Kawada K., Suzuki H. Clinical study on expectorant effect of ambroxol hydrochloride in chronic pulmonary diseases. Jpn. Pharmacol. Ther. 1992, 20(7):2629-2638.
20. Nakajima H., Kajiura S., Noda M., Watanabe Y., Arai T., Sano H., et al. Clinical effect of ambroxol (ponophen) on expectorantion in patients with chronic respiratory disease. Jpn. Pharmacol. Ther. 1993, 21(4):1163-1173.
21. Abe T., Setoguchi Y., Kono Y., Togashi Y., Sugiyama S., Tanakadate M., et al. Effects of inhaled tiotropium plus transdermal tulobuterol versus tiotropium alone on impulse oscillation system (IOS)-assessed measures of peripheral airway resistance and reactance, lung function and quality of life in patients with COPD: a randomized crossover study. Pulm. Pharmacol. Ther. 2011, 24(5):617-624.
22. Hashida S., Ishikawa E., Nakamichi N., Sekino H. Concentration of egg white lysozyme in the serum of healthy subjects after oral administration. Clin. Exp. Pharmacol. Physiol. 2002, 29:79-83.
23. Nagaoka S., Takishima T., Nagano J., Kawakami Y., Kitamura S., Kawakami M., et al. Phase III clinical study of SS320A -double blind trial in comparison with pracebo. J. Clin. Ther. Med. 2002, 18(1):109-140.
24. Kon S.S., Canavan J.L., Jones S.E., Nolan C.M., Clark A.L., Dickson M.J., et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir. Med. 2014 Mar, 2(3):195-203.
25. Hogg J., Chu F., Utokaparch S., Woods R., Elliott M., Buzatu L., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004, 350(26):2645-2653.
26. Piatti G., Ambrosetti U., Santus P., Allegra L. Effects of salmeterol on cilia and mucus in COPD and pneumonia patients. Pharmacol. Res. 2005, 51:165-168.
27. Fahy J.V., Dickey Dickey BF. Airway mucus function and dysfunction. New Eng. J. Med. 2010, 363:2233-2247.
28. Naito S., Tominaga H., Uno J., Dohiguchi Y., Hamaguchi K. The anti-inflammatory effect of lysozyme hydrochloride on rabbits with different doses. Jpn. Pharmacol. Ther. 1986, 14:4165-4169.
29. Fukawa K., Irino O., Watanabe A. Pharmacological effects of lysozyme and its reaction with serum proteins. Pharmacometrics 1981, 21:587-593.
30. Sakurai T., Iesato K., Sakao S., Saito K., Tatsumi K., Shirasawa H. Lysozyme hydrochloride inhibits cytokines in epithelial cells with respiratory syncytial virus infection: a brief report. Int. J. Pharm. Sci. Drug Res. 2015, 7(1):126-128.
31. Ichinose M., Sugiura H., Yamagata S., Koarai A., Shirato K. Increase in reacrive nitrogen species production in cronic obstructive pulmonary disease airways. Am. J. Respir. Crit. Care Med. 2000, 162:701-706.
32. Matsunaga K., Hirano T., Kawayama T., Tsuburai T., Nagase H., Aizawa H., et al. Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. Allergol. Int. 2010, 59:363-367.
33. Tamada T., Sugiura H., Takahashi T., Matsunaga K., Kimura K., Katsumata U., et al. Biomarker-based detection of ashma-COPD overlap syndrome in COPD populations. Int. J. Chron. Obstr. Pulmon. Dis. 2015, 10:2169-2176.
34. Breyer M.K., Rutten E.P., Locantore N.W., Watkins M.L., Miller B.E., Wouters E.F. ECLIPSE investigators (evaluation of COPD longitudinally to identify predictive surrogate endpoints). Dysregulated adipokine metabolism in chronic obstructive pulmonary disease. Eur. J. Clin. Invest. 2012, 42(9):983-991.
35. James A., Ono J., Kupczyk M., Ohta S., Izuhara K., Dahlen S.E.K. Controlled oral steroid intervention decreases serum periostin levels in asthmatic patients. Am. J. Respir. Crit. Care Med. 2013, 187. A6005.
36. Nakamura Y., Nagashima H., Ohta S., Ono J., Yamaguchi K., Izuhara K. Periostin in the bronchial lavage fluid of asthma patients. Allergol. Int. 2015, 64:209-210.